Honeywell International Inc. Acquires 3,100 Shares of Bristol-Myers Squibb Co. (BMY)
Honeywell International Inc. raised its stake in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 0.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 702,400 shares of the biopharmaceutical company’s stock after buying an additional 3,100 shares during the period. Bristol-Myers Squibb accounts for about 1.3% of Honeywell International Inc.’s portfolio, making the stock its 18th largest position. Honeywell International Inc.’s holdings in Bristol-Myers Squibb were worth $51,662,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. DnB Asset Management AS boosted its stake in shares of Bristol-Myers Squibb by 24.7% in the first quarter. DnB Asset Management AS now owns 273,706 shares of the biopharmaceutical company’s stock valued at $17,484,000 after buying an additional 54,200 shares during the period. CENTRAL TRUST Co purchased a new stake in shares of Bristol-Myers Squibb during the first quarter valued at $11,545,000. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in shares of Bristol-Myers Squibb by 14.8% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 379,727 shares of the biopharmaceutical company’s stock valued at $24,257,000 after buying an additional 48,888 shares during the period. Capstone Asset Management Co. boosted its stake in shares of Bristol-Myers Squibb by 9.3% in the first quarter. Capstone Asset Management Co. now owns 33,747 shares of the biopharmaceutical company’s stock valued at $2,156,000 after buying an additional 2,870 shares during the period. Finally, Exxonmobil Investment Management Inc. TX boosted its stake in shares of Bristol-Myers Squibb by 8.7% in the first quarter. Exxonmobil Investment Management Inc. TX now owns 406,473 shares of the biopharmaceutical company’s stock valued at $25,965,000 after buying an additional 32,540 shares during the period. 72.91% of the stock is owned by institutional investors and hedge funds.
Bristol-Myers Squibb Co. (NYSE:BMY) traded up 0.53% during midday trading on Friday, hitting $56.72. 6,002,454 shares of the company traded hands. The stock has a market cap of $94.77 billion, a P/E ratio of 33.17 and a beta of 0.61. The stock has a 50 day moving average of $58.51 and a 200 day moving average of $67.50. Bristol-Myers Squibb Co. has a 12-month low of $55.02 and a 12-month high of $77.12.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. Bristol-Myers Squibb had a return on equity of 24.92% and a net margin of 16.63%. The firm had revenue of $4.90 billion for the quarter, compared to analyst estimates of $4.60 billion. During the same period last year, the company earned $0.53 earnings per share. The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. Equities research analysts predict that Bristol-Myers Squibb Co. will post $2.62 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be given a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 2.69%. The ex-dividend date of this dividend is Wednesday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 87.36%.
Several analysts recently weighed in on BMY shares. TheStreet raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, May 31st. Vetr raised shares of Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.79 price objective on the stock in a report on Tuesday, June 7th. Jefferies Group raised their price objective on shares of Bristol-Myers Squibb from $76.00 to $78.00 and gave the stock a “hold” rating in a report on Tuesday, June 14th. Deutsche Bank AG reissued a “hold” rating on shares of Bristol-Myers Squibb in a report on Wednesday, June 15th. Finally, Goldman Sachs Group Inc. reissued a “buy” rating on shares of Bristol-Myers Squibb in a report on Wednesday, July 6th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and an average price target of $69.64.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 23,200 shares of the stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $72.14, for a total value of $1,673,648.00. Following the sale, the director now directly owns 403,094 shares of the company’s stock, valued at $29,079,201.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.24% of the stock is owned by company insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.